Fingolimod for relapsing multiple sclerosis: an update

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thymic emigration: Sphingosine-1-phosphate receptor-1-dependent models and beyond

(2009) Michael B. Drennan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ketoconazole Increases Fingolimod Blood Levels in a Drug Interaction via CYP4F2 Inhibition

(2009) John M. Kovarik et al.   JOURNAL OF CLINICAL PHARMACOLOGY

FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses

(2009) Dimitrios Papadopoulos et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors

(2009) Florian Mullershausen et al.   Nature Chemical Biology

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT

(2009) F. Leypoldt et al.   NEUROLOGY

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod

(2008) Veronique E. Miron et al.   AMERICAN JOURNAL OF PATHOLOGY

New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets

(2008) Andrea Huwiler et al.   BIOCHEMICAL PHARMACOLOGY

FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage

(2008) Carolyn A. Foster et al.   BRAIN PATHOLOGY

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

(2008) John M. Kovarik et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

FTY720 (fingolimod) for relapsing multiple sclerosis

(2008) Alejandro Horga et al.   Expert Review of Neurotherapeutics

Accumulation of Fingolimod (FTY720) in Lymphoid Tissues Contributes to Prolonged Efficacy

(2008) S.-C. Sensken et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Central nervous system-directed effects of FTY720 (fingolimod)

(2008) Veronique E. Miron et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

(2008) Rocio S. Lopez-Diego et al.   NATURE REVIEWS DRUG DISCOVERY

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY

The B Cell — Old Player, New Position on the Team

(2008) Henry F. McFarland   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 modulates human oligodendrocyte progenitor process extension and survival

(2007) Veronique E. Miron et al.   ANNALS OF NEUROLOGY

Brain sphingosine-1-phosphate receptors: Implication for FTY720 in the treatment of multiple sclerosis

(2007) Kumlesh K. Dev et al.   PHARMACOLOGY & THERAPEUTICS